Peter hecht cyclerion
WebCyclerion Therapeutics is funded by 8 investors. MFN Partners and Peter M. Hecht are the most recent investors. Funding Rounds Number of Funding Rounds 3 Total Funding Amount $217M Cyclerion Therapeutics has raised a total of $217M in funding over 3 rounds. Their latest funding was raised on Jun 4, 2024 from a Post-IPO Equity round. WebThe Sacramento Bee. 2005 - Jun 202412 years. • Senior writer covering California issues and news for The Sacramento Bee and McClatchy …
Peter hecht cyclerion
Did you know?
WebPeter M. Hecht is the Co-Founder & CEO at Cyclerion Therapeutics. Additionally, Peter M. Hecht has had 1 past job as the Co-Founder and CEO at Ironwood Pharmaceuticals. … WebAs Chief Executive Officer at CYCLERION THERAPEUTICS, Peter M. Hecht Ph.D. made $108,220 in total compensation. Of this total $100,000 was received as a salary, $0 was received as a bonus, $0 was received in stock options, $0 was awarded as stock and $8,220 came from other types of compensation.
Web阅读数：859 ... Web4. jún 2024 · Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the...
Web21. dec 2024 · I am pleased that we will continue to benefit from Bill’s strategic acumen going forward. I also want to express my deep appreciation to Amy Schulman for her service as a founding member of the... Web13. feb 2024 · Peter Hecht, PhD. 13th February 2024. Our Chief Executive Officer, Peter Hecht, PhD, served as the co-founder and chief executive officer of Ironwood …
WebPeter M. Hecht founded Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc. He is Chief Executive Officer & Director at Cyclerion Therapeutics, Inc. He is also on the board of Kallyope, Inc. and Mythic Therapeutics, Inc. In the past he occupied the position of Chief Executive Officer & Director at Ironwood Pharmaceuticals, Inc.
Web20. okt 2024 · Cyclerion Therapeutics has decided to suspend the development of olinciguat, its investigational oral therapy for sickle cell disease (SCD), after the treatment failed to show adequate activity in a Phase 2 clinical trial, the company announced. naruto shippuden dubbed 230WebCyclerion Therapeutics 245 First Street Riverview II, 18th Floor Cambridge, MA 02142 Phone: 857-327-8778 Email: [email protected] Fax: 617-890-6595 Investor Relations or Media Inquiries: [email protected] Partnering Inquiries: [email protected] Sponsorship Inquiries: [email protected] Privacy Policy ACCEPT mellon shareholder servicesWeb27. júl 2024 · Peter Hecht, Cyclerion Therapeutics CEO. April 3, 2024 11:03 AM EDT Updated 11:21 AM. ... Cyclerion Therapeutics is looking for a way to keep its drug development ambitions alive, and the biotech ... mellon scholarshipWeb23. nov 2024 · Peter Hecht, Cyclerion Therapeutics CEO. April 3, 2024 11:03 AM EDT Updated 11:21 AM. ... Cyclerion Therapeutics is looking for a way to keep its drug development ambitions alive, and the biotech ... mellons and cantalope for diabeticWeb4. jún 2024 · Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional … naruto shippuden dubbed 24Web31. júl 2024 · Photo: Peter Hecht, CEO of Cyclerion Cyclerion’s pipeline has five sGC stimulator programs, including olinciguat, an experimental sGC in phase 2 studies for sickle cell disease, a genetic blood disorder affecting hemoglobin, a protein in red blood cells that carries oxygen throughout the body. mellonsecurecookieWeb6. okt 2024 · Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments for mitochondrial diseases, including MELAS. Cyclerion’s … mellon services gmbh